Invention Grant
- Patent Title: Cladribine regimen for treating progressive forms of multiple sclerosis
-
Application No.: US16199119Application Date: 2018-11-23
-
Publication No.: US10849919B2Publication Date: 2020-12-01
- Inventor: Fernando Dangond , Matthias Dotzauer
- Applicant: Merck Patent GmbH
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Grüneberg and Myers PLLC
- Main IPC: A61P37/02
- IPC: A61P37/02 ; A61K31/7076 ; A61K9/20 ; A61P25/00 ; A61K38/21

Abstract:
Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
Public/Granted literature
- US20190167707A1 Cladribine regimen for treating progressive forms of Multiple Sclerosis Public/Granted day:2019-06-06
Information query